Study shows noninferiority of Herceptin biosimilar | Bill would exempt CME payments from public reporting | CMS issues ACA insurance exchange enrollment manuals
July 22, 2016
FOLLOW PCMA ON TWITTER  Twitter
PCMA SmartBrief
News for the PBM Industry
SIGN UP ⋅   FORWARD ⋅   ARCHIVE
Featured Story
Study shows noninferiority of Herceptin biosimilar
Researchers found "no clinically meaningful differences" between Roche Holding's breast cancer drug Herceptin and ABP 980, a biosimilar version of the drug being developed by Amgen and Allergan.
The Wall Street Journal (tiered subscription model) (7/21) 
LinkedIn Twitter Facebook Google+ Email
Legislative & Regulatory News
Bill would exempt CME payments from public reporting
Drug and medical device makers would not have to report spending on continuing medical education, medical journals or textbooks for physicians under a Senate bill supported by the American Medical Association and other physician groups.
STAT/Pharmalot (7/21) 
LinkedIn Twitter Facebook Google+ Email
CMS issues ACA insurance exchange enrollment manuals
The CMS manual for the 2017 Affordable Care Act open enrollment period covers the rules and procedures for issuers of qualified health plans and qualified dental plans offered on publicly run individual and small-business exchanges; individuals and employers who seek coverage through the exchanges; and brokers, agents and others who provide help to people who have or are seeking coverage.
Health Affairs Blog (7/20) 
LinkedIn Twitter Facebook Google+ Email
Humana to exit some ACA exchanges
Humana will sell health insurance plans in the individual market in 11 states next year, down from 19 in 2016, and the insurer will sell individual plans in "no more than 156 counties," down from 1,351 counties, the insurer announced.
Modern Healthcare (tiered subscription model) (7/21) 
LinkedIn Twitter Facebook Google+ Email
Drug Industry Spotlight
Pair of studies to focus on anticoagulants with $6.5M
Two studies comparing anticoagulants will receive about $6.5 million from the Patient-Centered Outcomes Research Institute. The University of California at San Francisco will study the effectiveness of five drugs with $3.5 million in funding, while Boston's Brigham and Women's Hospital will receive $2.9 million to examine four anticoagulants.
CardiovascularBusiness.com (7/21) 
LinkedIn Twitter Facebook Google+ Email
  
  
The greatest mistake you can make in life is to continually be afraid you will make one.
Elbert Hubbard,
writer and artist
LinkedIn Twitter Facebook Google+ Email
  
  
Learn more about PCMA:
Upcoming PCMA Events | PCMA Newsroom
Become a PCMA Affiliate
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 266 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

Contact PCMA
Charles Cote
Vice President, Strategic Communications
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2016 SmartBrief, Inc.®
Privacy policy |  Legal Information